Wei Wang

Associate Professor

Building 2, Room 112, 350 Shushanhu Road, Hefei, 230031, P.R. China

Tel:+86-551-65595013

E-mail: wwang@hmfl.ac.cn

EDUCATION BACKGROUND

Apr. 2012 Ph.D. Biological Sciences, Tokyo Metropolitan University, Japan

Jun. 2008 M.S. Applied Chemistry, Tianjin University, China

Jun. 2006 B.S. Chemical Engineering Technology, Tianjin University, China


RESEARCH EXPERIENCE

2018/03-present, Associate Professor, CAS

2014/09-2018-02, Assistant Professor, CAS

2014/09-present, Visiting Researcher, RIKEN

2012/04-2014/09, Postdoc Research Fellow, RIKEN

2009/04-2012/03, Junior Research Assistant, RIKEN

PUBLICATIONS

  1. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, and Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01907.
  2. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang#, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Cai-Hong Yun*, Jing Liu*, Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med. Chem. 2017, DOI: 10.1016/j.ejmech.2017.03.001.
  3. Yasodha Manandhar#, Wei Wang#, Jin Inoue, Nobuhiro Hayashi, Takanori Uzawa, Yutaka Ito, Toshiro Aigaki, and Yoshihiro Ito, Interactions of in vitro selected fluorogenic peptide aptamers with calmodulin. Biotechnol. Lett. 2017, 39(3): 375-382.
  4. Wei Wang, Liping Zhu, Yoshinori Hirano, Marziyeh Karamiavargani, Seiichi Tada, Guanxin Zhang, Takanori Uzawa, Deqing Zhang, Takuji Hirose, Makoto Taiji, and Yoshihiro Ito, Fluorogenic enhancement of in vitro selected binding peptide ligand by replacement of fluorescent group. Anal. Chem. 2016, 88(16): 7991-7997.
  5. Qiang Wang, Feiyang Liu, Beilei Wang, Fengming Zou, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*, Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-289.
  6. Wei Wang, Yoshinori Hirano, Takanori Uzawa, Makoto Taiji, and Yoshihiro Ito, Peptide-Assisted Enhancement of Inhibitory Effects of Small Molecular Inhibitors for Kinases. Bull. Chem. Soc. Jpn. 2016, 89(4): 444-446.
  7. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong#, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun*, Zhimin Zhai*, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7(29): 45562-45574.
  8. Hong Wu#, Aoli Wang#, Ziping Qi#, Xixiang Li#, Cheng Chen#, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016, 30(10): 2112-2116.
  9. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen#, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, and Qingsong Liu*. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-79.
  10. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu,Liu Qingsong, Discovery of (R)-1-(3-(4-amino-3-(4-phen- oxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin- 1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58(24): 9625-9638.
  11. Liping Zhu, Wei Wang, Haixu Zhao, Muye Xu, Seiichi Tada, Takanori Uzawa, Mingzhe Liu, and Yoshihiro Ito, Dual functional peptide carrying in vitro selected catalytic and binding activities. Org. Biomol. Chem. 2015, 13(38): 9808-9812.
  12. Yasodha Manandhar, Tara Bahadur K.C., Wei Wang, Takanori Uzawa, Toshiro Aigaki, and Yoshihiro Ito, In vitro selection of a peptide aptamer that changes fluorescence in response to verotoxin. Biotechnol. Lett. 2015, 37(3): 619-625.
  13. Seiichi Tada, Qingmin Zang, Wei Wang, Masuki Kawamoto, Mingzhe Liu, Michiru Iwashita, Takanori Uzawa, Daisuke Kiga, Masayuki Yamamura and Yoshihiro Ito, In vitro selection of a photo-responsive peptide aptamer to glutathione-immobilized microbeads. J. Biosci. Bioeng. 2015, 119(2): 137-139.
  14. Wei Wang, Yoshinori Hirano, Takanori Uzawa, Minzhe Liu, Makoto Taiji and Yoshihiro Ito, In vitro selection of a peptide aptamer that potentiates inhibition of cyclin-dependent kinase by purvalanol. Med. Chem. Comm. 2014, 5(9): 1400-1403.
  15. Wei Wang, Takanori Uzawa, Naoya Tochio, Jumpei Hamatsu, Yoshinori Hirano, Seiichi Tada, Hisao Saneyoshi, Takanori Kigawa, Nobuhiro Hayashi, Yutaka Ito, Makoto Taiji, Toshiro Aigaki, and Yoshihiro Ito, A fluorogenic peptide probe developed by in vitro selection using tRNA carrying a fluorogenic amino acid. Chem. Coummn. 2014, 50(22): 2962-2964.
  16. Seiichi Tada, Wei Wang, Zha Li, Takanori Uzawa, and Yoshihiro Ito, Creation of Novel Functional Peptides by Mimicking Darwinian Evolution. KOBUNSHI RONBUNSHU 2013, 70(7): 317-325.
  17. Takanori Uzawa,？Seiichi Tada,？Wei Wang,？and Yoshihiro Ito, Expansion of the aptamer library from a “natural soup” to an “unnatural soup”. Chem. Commun. 2013, 49(18): 1786-1795.
  18. Wei Wang, Shuta Hara, Mingzhe Liu, Toshiro Aigaki, Shigeru Shimizu, and Yoshihiro Ito, Polypeptide aptamer selection using a stabilized ribosome display. J. Biosci. Bioeng. 2011, 112(5): 5515-5517.
  19. Xiaohui Cao, Ge Wang, Richeng Zhang, Yingying Wei, Wei Wang, Huichao Sun, and Ligong Chen, Proline-based reduced dipeptides as recyclable and highly enantioselective organocatalysts for asymmetric Michael addition. Org. Biomol. Chem. 2011, 9(19): 6487-6490.

Book Chapters

  1. Shuta Hara, Mingzhe Liu, Wei Wang, Muye Xu, Zha Li, and Yoshihiro Ito. Stabilized ribosome display for in vitro selection, in Ribosome Display and Related Display Technologies: Methods and Protocols. Humana Press, Cambridge, 2011.

PATENTS

  1. 发明名称：一种新型的PDGFR激酶抑制剂及其用途
    发明人： 刘青松，刘静， 王强， 刘飞扬，亓爽，王蓓蕾，王文超，王傲莉，王伟，陈程，刘晓川，蒋宗儒，胡祯全，任涛，王黎
    专利受理号：201610811854.7
  2. 发明名称：一种选择性的C-KIT激酶抑制剂
    发明人： 刘青松，刘静，王强，王蓓蕾，刘飞扬，亓爽，齐紫平，邹凤鸣，陈程，王文超，胡晨，刘晓川，王伟，王傲莉，王黎，胡祯全，任涛
    专利受理号：2201610210424.X
  3. 发明名称：一种新型布鲁顿酪氨酸激酶不可逆抑制剂
    发明人：刘静， 刘青松， 梁前茅，陈永飞，陈程，王傲莉，吴宏，余凯琳，王伟，胡晨，王文超，亓爽，王蓓蕾，王黎
    专利受理号：201610084082.1
  4. 发明名称：一种新型布鲁顿酪氨酸激酶不可逆抑制剂
    发明人：刘青松，刘静，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾
    专利受理号：201510547224.9